in, similar to placebo. * Bifeprunox patients experienced decreases in body weight, body mass index (BMI) and prolactin and had an extrapyramidal side effects profile similar to placebo. -- Weight, BMI and lipids were assessed in patients with acute exacerbations of schizophrenia in an analysis of another Phase 3, six-week, randomized, double-blind, placebo-controlled active- referenced study: * Weight decreases and minor reductions in BMI were observed in patients who received bifeprunox. * Cholesterol and TG levels improved in patients who received bifeprunox. Efficacy and Metabolic Effects -- A pooled analysis examined efficacy and metabolic effects of bifeprunox from one six-month, randomized, double-blind, placebo-controlled study in stable adult patients and four six-week, randomized, double-blind, placebo-controlled active-referenced studies in patients with acute exacerbations of schizophrenia: * Evaluations included time to deterioration in a six-month study, change in Positive and Negative Syndrome Scale (PANSS) total score in six-week studies, and body weight and lipids in all studies. * In patients who received bifeprunox, weight decreases and improvements in lipid parameters were observed along with significant differences in primary efficacy measurements versus placebo. Pharmacokinetic Analysis -- This abstract reported a pooled analysis of 21 clinical pharmacology studies that included pharmacokinetic profiles after single and multiple doses: * Bifeprunox was absorbed within two hours at all dose levels after oral administration. * Food had no relevant effect on the pharmacokinetics of bifeprunox.

In these analyses, the most common side effects reported with bifeprunox (incidence of gre
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Managing Preanalytical Processes for Patient Safety
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
6. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
7. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
11. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care